CAR-T cell therapy for late-relapse aggressive lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of aggressive B-cell lymphoma (like DLBCL) that came back after 12 months to 5 years after finishing your first treatment
- You received only one prior line of chemotherapy that included rituximab and a CHOP-like regimen
- Your cancer shows up on a PET scan and you are healthy enough for a stem cell collection procedure
- You do not have active lymphoma in the brain, serious heart or lung problems, or other significant medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.